Cohort demographics and clinical characteristics
| Patient characteristics (No=432) | No (%) |
| General characteristics | |
| Mean age (SD) | 63.4 (12.1) |
| Male | 246 (56.9) |
| Caucasian race | 324 (75.0) |
| Cirrhosis aetiology | |
| Alcoholic cirrhosis | 162 (37.5) |
| Cryptogenic/unknown | 97 (22.5) |
| Metabolic (NASH, haemochromatosis, Wilson’s) | 87 (20.1) |
| Viral hepatitis B and C | 53 (12.3) |
| Autoimmune (AIH, PBC, PSC) | 11 (2.5) |
| Combination of alcoholic liver disease and other aetiology | 22 (5.1) |
| Medical comorbidities | |
| Atrial fibrillation | 50 (11.6) |
| Venous thromboembolic disease | 23 (5.3) |
| CVA or TIA | 26 (6.0) |
| Coronary artery disease or peripheral artery disease | 89 (20.6) |
| Encounter characteristics (no=520) | |
| Laboratory values | Median (IQR) |
| WCC (x 109/L) | 6.3 (4.4–9.6) |
| Platelet count (x109/L) | 116 (77–174) |
| MELD score (n=473) | 17 (13–23) |
| Haemoglobin (g/dL) | 10.8 (9.1–12.6) |
| Serum creatinine (mg/dL) | 1.3 (0.9–2.1) |
| International normalised ratio | 1.4 (1.2–1.8) |
| Total bilirubin (mg/dL) | 2 (1.1–3.7) |
| Medications | No (%) |
| Anticoagulant use (direct oral anticoagulants/warfarin) | 67 (12.9) |
| Aspirin use | 196 (37.7) |
| Other antiplatelet agent (ticagrelor, prasugrel, clopidogrel) | 61 (11.7) |
.AIH, autoimmune hepatitis; MELD, model for end stage liver disease; NASH, non-alcoholic steatohepatitis; PBC, primary biliary cholangitis; PSC, primary sclerosing cholangitis; WCC, white cell count.